Johns Hopkins University, Baltimore, Maryland.
Vanderbilt University Medical Center, Nashville, Tennessee.
Arthritis Rheumatol. 2023 Dec;75(12):2240-2251. doi: 10.1002/art.42632. Epub 2023 Oct 30.
Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) experience worse survival and derive less benefit from pulmonary vasodilator therapies than patients with idiopathic PAH (IPAH). We sought to identify differential metabolism in patients with CTD-PAH versus patients with IPAH that might underlie these observed clinical differences.
Adult participants with CTD-PAH (n = 141) and IPAH (n = 165) from the Pulmonary Vascular Disease Phenomics (PVDOMICS) study were included. Detailed clinical phenotyping was performed at cohort enrollment, including broad-based global metabolomic profiling of plasma samples. Participants were followed prospectively for ascertainment of outcomes. Supervised and unsupervised machine learning algorithms and regression models were used to compare CTD-PAH versus IPAH metabolomic profiles and to measure metabolite-phenotype associations and interactions. Gradients across the pulmonary circulation were assessed using paired mixed venous and wedged samples in a subset of 115 participants.
Metabolomic profiles distinguished CTD-PAH from IPAH, with patients with CTD-PAH demonstrating aberrant lipid metabolism with lower circulating levels of sex steroid hormones and higher free fatty acids (FAs) and FA intermediates. Acylcholines were taken up by the right ventricular-pulmonary vascular (RV-PV) circulation, particularly in CTD-PAH, while free FAs and acylcarnitines were released. In both PAH subtypes, dysregulated lipid metabolites, among others, were associated with hemodynamic and RV measurements and with transplant-free survival.
CTD-PAH is characterized by aberrant lipid metabolism that may signal shifted metabolic substrate utilization. Abnormalities in RV-PV FA metabolism may imply a reduced capacity for mitochondrial beta oxidation within the diseased pulmonary circulation.
与结缔组织病相关的肺动脉高压(CTD-PAH)患者的生存状况比特发性肺动脉高压(IPAH)患者更差,从肺血管扩张剂治疗中获益更少。我们试图确定 CTD-PAH 患者与 IPAH 患者之间的差异代谢,这可能是这些观察到的临床差异的基础。
纳入来自肺血管疾病表型(PVDOMICS)研究的 CTD-PAH(n=141)和 IPAH(n=165)成年参与者。在队列入组时进行详细的临床表型分析,包括对血浆样本进行广泛的基础全局代谢组学分析。前瞻性随访参与者以确定结局。使用监督和无监督机器学习算法和回归模型来比较 CTD-PAH 与 IPAH 的代谢组学特征,并测量代谢物-表型关联和相互作用。在 115 名参与者的亚组中,使用配对的混合静脉和楔入样本评估肺循环梯度。
代谢组学特征区分了 CTD-PAH 和 IPAH,CTD-PAH 患者表现出异常的脂质代谢,循环中性激素水平较低,游离脂肪酸(FA)和 FA 中间产物水平较高。酰基胆碱被右心室-肺血管(RV-PV)循环摄取,尤其是在 CTD-PAH 中,而游离 FA 和酰基肉碱被释放。在两种 PAH 亚型中,除其他外,失调的脂质代谢物与血液动力学和 RV 测量值以及无移植存活相关。
CTD-PAH 的特征是异常的脂质代谢,这可能表明代谢底物利用发生了转移。RV-PV FA 代谢异常可能意味着疾病肺循环中线粒体β氧化的能力降低。